Cargando…

Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data

Recently, guidelines for endometrial cancer (EC) were released that guide treatment decisions according to the tumors’ molecular profiles. To date, no real-world data regarding the clinical feasibility of molecular profiling have been released. This retrospective, monocentric study investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberndorfer, Felicitas, Moling, Sarah, Hagelkruys, Leonie Annika, Grimm, Christoph, Polterauer, Stephan, Sturdza, Alina, Aust, Stefanie, Reinthaller, Alexander, Müllauer, Leonhard, Schwameis, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830511/
https://www.ncbi.nlm.nih.gov/pubmed/33467460
http://dx.doi.org/10.3390/jpm11010048
_version_ 1783641432132681728
author Oberndorfer, Felicitas
Moling, Sarah
Hagelkruys, Leonie Annika
Grimm, Christoph
Polterauer, Stephan
Sturdza, Alina
Aust, Stefanie
Reinthaller, Alexander
Müllauer, Leonhard
Schwameis, Richard
author_facet Oberndorfer, Felicitas
Moling, Sarah
Hagelkruys, Leonie Annika
Grimm, Christoph
Polterauer, Stephan
Sturdza, Alina
Aust, Stefanie
Reinthaller, Alexander
Müllauer, Leonhard
Schwameis, Richard
author_sort Oberndorfer, Felicitas
collection PubMed
description Recently, guidelines for endometrial cancer (EC) were released that guide treatment decisions according to the tumors’ molecular profiles. To date, no real-world data regarding the clinical feasibility of molecular profiling have been released. This retrospective, monocentric study investigated the clinical feasibility of molecular profiling and its potential impact on treatment decisions. Tumor specimens underwent molecular profiling (testing for genetic alterations, (immune-)histological examination of lymphovascular space invasion (LVSI), and L1CAM) as part of the clinical routine and were classified according to the European Society for Medical Oncology (ESMO) classification system and to an integrated molecular risk stratification. Shifts between risk groups and potential treatment alterations are described. A total of 60 cases were included, of which twelve were excluded (20%), and eight of the remaining 48 were not characterized (drop-out rate of 16.7%). Molecular profiling revealed 4, 6, 25, and 5 patients with DNA polymerase-epsilon mutation, microsatellite instability, no specific molecular profile, and TP53 mutation, respectively. Three patients had substantial LVSI, and four patients showed high L1CAM expression. Molecular profiling took a median of 18.5 days. Substantial shifts occurred between the classification systems: four patients were upstaged, and 19 patients were downstaged. Molecular profiling of EC specimens is feasible in a daily routine, and new risk classification systems will change treatment decisions substantially.
format Online
Article
Text
id pubmed-7830511
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78305112021-01-26 Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data Oberndorfer, Felicitas Moling, Sarah Hagelkruys, Leonie Annika Grimm, Christoph Polterauer, Stephan Sturdza, Alina Aust, Stefanie Reinthaller, Alexander Müllauer, Leonhard Schwameis, Richard J Pers Med Article Recently, guidelines for endometrial cancer (EC) were released that guide treatment decisions according to the tumors’ molecular profiles. To date, no real-world data regarding the clinical feasibility of molecular profiling have been released. This retrospective, monocentric study investigated the clinical feasibility of molecular profiling and its potential impact on treatment decisions. Tumor specimens underwent molecular profiling (testing for genetic alterations, (immune-)histological examination of lymphovascular space invasion (LVSI), and L1CAM) as part of the clinical routine and were classified according to the European Society for Medical Oncology (ESMO) classification system and to an integrated molecular risk stratification. Shifts between risk groups and potential treatment alterations are described. A total of 60 cases were included, of which twelve were excluded (20%), and eight of the remaining 48 were not characterized (drop-out rate of 16.7%). Molecular profiling revealed 4, 6, 25, and 5 patients with DNA polymerase-epsilon mutation, microsatellite instability, no specific molecular profile, and TP53 mutation, respectively. Three patients had substantial LVSI, and four patients showed high L1CAM expression. Molecular profiling took a median of 18.5 days. Substantial shifts occurred between the classification systems: four patients were upstaged, and 19 patients were downstaged. Molecular profiling of EC specimens is feasible in a daily routine, and new risk classification systems will change treatment decisions substantially. MDPI 2021-01-15 /pmc/articles/PMC7830511/ /pubmed/33467460 http://dx.doi.org/10.3390/jpm11010048 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Oberndorfer, Felicitas
Moling, Sarah
Hagelkruys, Leonie Annika
Grimm, Christoph
Polterauer, Stephan
Sturdza, Alina
Aust, Stefanie
Reinthaller, Alexander
Müllauer, Leonhard
Schwameis, Richard
Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
title Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
title_full Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
title_fullStr Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
title_full_unstemmed Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
title_short Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data
title_sort risk reclassification of patients with endometrial cancer based on tumor molecular profiling: first real world data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830511/
https://www.ncbi.nlm.nih.gov/pubmed/33467460
http://dx.doi.org/10.3390/jpm11010048
work_keys_str_mv AT oberndorferfelicitas riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata
AT molingsarah riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata
AT hagelkruysleonieannika riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata
AT grimmchristoph riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata
AT polterauerstephan riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata
AT sturdzaalina riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata
AT auststefanie riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata
AT reinthalleralexander riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata
AT mullauerleonhard riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata
AT schwameisrichard riskreclassificationofpatientswithendometrialcancerbasedontumormolecularprofilingfirstrealworlddata